IMMUNOLOGY OF MULTIPLE SCLEROSIS
DOI:
https://doi.org/10.24293/ijcpml.v24i2.1323Keywords:
Multiple sclerosis, autoimmuneAbstract
Multiple Sclerosis (MS) is an autoimmune disease that causes myelin destruction in the Central Nervous System (CNS). Characteristics of this disease are perivascular infiltration by inflammatory cells, demyelination and loss of axons, accompanied by multiple plaque formation in the brain and spinal cord. According to the National Multiple Sclerosis Society, 400,000 people suffer from MS in the United States and about 2.5 million people worldwide. The disease is usually diagnosed in patients aged 20-45 years and more often found in females than males with a ratio of 2: 1. Nevertheless, the etiology of MS is still unknown, but it is suspected that genetic and environmental factors may induce a response to central nervous system autoantigen, such as Epstein-Barr Virus (EBV) infection. It then causes edema, demyelination, axon destruction and loss of oligodendrosites, resulting in neurological deficits, plaque formation, scarring and reduced brain volume. Multiple sclerosis symptoms and signs actually vary greatly depending on the location of the lesions and the course of the various diseases. Multiple sclerosis, moreover, can be divided into four clinical categories, namely Clinically Isolated Syndrome (CIS), Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Primary Progressive Multiple Sclerosis (PPMS). Diagnosis of Multiple sclerosis is established based on clinical symptoms and supporting investigations, such as MRI, CSF and neurological examination. In CSF examination, oligoclonal bands are found in over 90% of patients, considered as one of the laboratory criteria supporting the diagnosis of MS. There are four kinds of drugs that have been approved by the FDA as disease modifying therapy for the initial treatment of MS patients, namely interferon beta-1a, subcutaneous (SC) interferon beta-1a, interferon beta-1b and glatiramer acetate In conclusion, life expectancy in MS patients is only slightly reduced and survival is related to the disability occurred.
Downloads
References
Brass S, Weiner H, Hafler D. Multiple Sclerosis. In: Rose N, and Mackay I. The Autoimmune Disease. USA, Elsevier, 2006; 615-27.
Milo R, and Miller A. Multiple Sclerosis. In: Shoenfeld Y, Cervera R, Gershwin M. Diagnostic Criteria in Autoimmune Disease. USA, Humana Press, 2008; 401-6.
Tsokos G, and Virella G. Organ Spesific Autoimmune Disease. In: Virella G. Medical Immunology. 6th Ed., USA, Informa, 2007; 255-7.
Mumenthaler M, Mattle H, and Taub E. Fundamentals of Neurology. New York, Thieme, 2006; 156-60.
Chamberlin S, and Narins B. The Gale Encyclopedia of Neurological Disorders. USA, Thomson Gale, 2005; 561-5.
Chapel H, Haeney M, Misbah S, and Snowden N. Essential of Clinical Immunology. 6th Ed., UK, Wiley Blackwell, 2014; 314-8.
Pithadia A, Jain S, and Navale A. Pathogenesis and Treatment of Multiple Sclerosis (MS). The Internet Journal of Neurology, 2008; 10(2): 1-13.
Matilde Inglese. Multiple Sclerosis: New Insights, and Trends. Am J Neuroradiol, 2006; 27: 954-57.
Rejdak K, Jackson S, and Giovannoni G. Multiple Sclerosis: a Practical Overview for Clinicians. British Medical Bulletin, 2010; 95: 79-104.
Hoppenbrouwers I and Hintzen R. Genetics of Multiple Sclerosis. Biochymica et Biophysica Acta, 2011; 1812: 194-201.
Rohkamm R. Color Atlas of Neurology. New York, Thieme, 2004; 214-21.
Loma I, and Heymann R. Multiple Sclerosis: Pathogenesis, and Treatment. Current Neuropharmacology, 2011; 9: 409-16.
Palace J. Making the Diagnosis of Multiple Sclerosis. J neurol Neurosurg Psychiatry, 2001; 71(II): ii3-ii8.
Calabresi P. Diagnosis, and Management of Multiple Sclerosis. American Academy of Family Physician, 2004; 70(10): 1935-43.
Polman C, Reingold S, Banwell B, Clanet M, Cohen J, et al. Diagnostic Criteria of Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. American Neurological Association, 2011; 69: 292-302.
Deisenhammer F, Bartos A, Egg R, Gilhus N, Giovannoni G, et al. Routine Cerebrospinal Fluid (CSF) Analysis. In: Gilhus N, Barnes M, and Brainin M. European Handbook of Neurological Management: Volume 1. 2nd Ed., New York, Blackwell Publishing, 2011; 5-14.
Kottill WR. Cerebrospinal Fluid in Multiple Sclerosis. Annals of Indian Academy of Neurology, 2009; 12(4): 246-53.
Mayo Clinic Medcal Laboratories. Cerebrospinal Fluid (CSF) Indes IgG. Available from: http://www.mayomedicallaboratories.com/test-catalog. Accessed on December 17th 2016.
Mayo Clinic Medcal Laboratories. Oligoclonal Banding, Serum, and Spinal Fluid. Available at: http://www.mayomedicallaboratories.com/test-catalog. Accessed on: December 17th 2016.
Bloch S, Callin S, Coggrave M, Smith A, Dods V, et al. Multiple Sclerosis Information for Health and Social Care Professional. Available from: www. mstrust.org.uk. Accessed on: May 28th 2016.
Luzzio C. Multiple Sclerosis. Available from: www. emedicine.medscape.com/article/980685. Last Update: Jan 2016. Accessed on: May 28th 2016
